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Abstract
We have previously synthesized a series of hybrid compounds by linking ferulic acid to tacrine as multifunctional agents
based on the hypotheses that Alzheimer’s disease (AD) generates cholinergic deficiency and oxidative stress. Interestingly,
we found that they may have potential pharmacological activities for treating AD. Here we report for the first time that
tacrine-6-ferulic acid (T6FA), one of these compounds, can prevent amyloid-b peptide (Ab)-induced AD-associated
pathological changes in vitro and in vivo. Our results showed that T6FA significantly inhibited auto- and acetylcholinesterase
(AChE)-induced aggregation of Ab1–40 in vitro and blocked the cell death induced by Ab1–40 in PC12 cells. In an AD mouse
model by the intracerebroventricular injection of Ab1–40, T6FA significantly improved the cognitive ability along with
increasing choline acetyltransferase and superoxide dismutase activity, decreasing AChE activity and malondialdehyde level.
Based on our findings, we conclude that T6FA may be a promising multifunctional drug candidate for AD.
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Introduction
Alzheimer’s disease (AD) is a multifactorial neurodegenerative
disorder with progressive and devastating memory impairment
[1]. The AD patient brain is characterized by amyloid-b peptide
(Ab) deposits, neurofibrillary tangles, synapse loss, and extensive
oxidative stress. Ab-induced oxidative stress is indexed by protein
oxidation, lipid peroxidation, free radical formation, DNA
oxidation and neuronal cell death [2–3]. The majority of
therapeutic strategies and drug development approaches for AD
were based on dysfunction of acetylcholine to date, which mainly
improves the pathological symptom [4]. Inhibition of Ab fibril
aggregation and antioxidants are also viewed as promising
strategies to halt the progression of AD [5–8]. Unfortunately,
current ‘‘one-molecule-one-target’’ drugs are not effective strategy
to delay or block the progress of AD pathology because of multiple
causes, such as cholinergic deficiency, Ab and tau protein toxicity,
oxidative stress and so on. Now, ‘‘one-compound-multi-targets’’
strategy, which simultaneously aimed at targeting multiple
pathological processes, gradually shows its potential advantages
[9–10].
Tacrine (1, 2, 3, 4-tetrahydro-9-acridinamine, THA, 1, Figure 1)
is the first centrally acting cholinesterase inhibitor to be widely
applied for the loss of memory and intellectual decline in patients
of AD. Though some deficiencies of tacrine emerged gradually
including hepatotoxic effect and low-selective peripheral cholin-
ergic effect, recent studies have demonstrated its homo- and
hetero-dimers can improve and enlarge its biological profile with
less side-effects [9,11]. Ferulic acid (4-hydroxy-3- methoxycin-
namic acid, FA, 2, Figure 1), a bioactive component of Traditional
Chinese Medicine, has antioxidant and anti-inflammatory effects
[12], inhibits Ab fibril aggregation [13], and prevents Ab-
mediated toxicity both in vitro and in vivo [14–15]. Besides these
benefits in the central nervous system, FA also possesses
hepatoprotective effects which may prevent the hepatotoxic effect
of tacrine [16].
Previously, Fang et al and we synthesized and evaluated a series
of tacrine-ferulic acid hybrids as multipotent anti-AD drug
candidates [17–21]. These compounds have better acetylcholin-
esterase (AChE) inhibitory activity and comparable butyrylcholi-
nesterase (BuChE) inhibitory activity in relation to tacrine [17,18].
In addition, these compounds can also inhibit 1,1-Diphenyl-2-
picrylhydrazyl (DPPH) radical formation [17,19]. Some of them
have been proved to reverse scopolamine-induced cognitive
impairment in mice or rats with low hepatotoxicity [18–20].
Interestingly, novel ferulic acid and benzothiazole dimer deriva-
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inhibit fibril aggregation as FA [22–23]. These results suggest that
tacrine-ferulic acid hybrids might also inhibit the fibril aggregation
of Ab and Ab-mediated toxicity, potential targets for AD therapy
[5–8].
In this study, we examined the effects of tacrine-6-ferulic acid
(T6FA, Figure 1), a novel tacrine-ferulic acid dimer, on Ab
aggregation, Ab-induced cell death in vitro and cognitive
impairment in a mouse model of AD induced by aggregated Ab.
Materials and Methods
Materials
Ab1–40, the reverse sequences Ab40–1, Tacrine hydrochloride,
Donepezil hydrochloride, Human acetylcholinesterase (HuAChE)
and 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide
(MTT) were purchased from Sigma Chemical Co. (agency in
China). 2,7-dichlorofluoroescin diacetate (H2DCF-DA) were
purchased from Molecular Probes Co. (agency in China).
Tacrine-6-ferulic acid (purity .98%) was synthesized by our
laboratory [17]. RPMI 1640 medium, antibiotics (penicillin/
streptomycin), horse serum and fetal bovine serum were purchased
from Invitrogen (Grand Island, NY, U.S.A.). Each test compound
(tacrine, T6FA and ferulic acid) at a concentration of 50 mM was
dissolved in DMSO and further diluted with PBS. The final
concentration of DMSO was no more than 0.1% in the medium,
which did not affect cell viability. A fresh 10 mM stock solution of
H2DCF-DA was prepared in ethanol. Fresh T6FA (1 mg/mL) was
prepared in phosphate-buffered saline. The cells were pre-
incubated with 2–50 mM T6FA for 30 min before the addition
of 20 mMo fA b1–40. The commercial kits for the assay of AChE
(Cat #, A024), choline acetytransferase (Cat #, A079), superoxide
dismutase (Cat #, A001-1) and malondialdehyde (Cat #, A003-2)
were purchased from Nanjing Jiancheng Biotech Company, China
(www.njjcbio.com).
Assay of AChE-induced Ab aggregation [24]
Aliquots of 2 mLA b1–40, lyophilised from 2 mg/mL hexafluoro-
isopropanol solution and dissolved in DMSO, were incubated for
48 h at room temperature in 0.215 M sodium phosphate buffer
(pH 8.0) at a final concentration of 230 mM. For co-incubation
experiments aliquots (16 mL) of HuAChE (final concentration
2.30 mM, Ab/AChE molar ratio 100:1) and HuAChE in the
presence of 2 mL of the tested inhibitors in 0.215 M sodium
phosphate buffer pH 8.0 solution (final inhibitor concentration
ranging between 50 and 100 mM) were added. Blanks containing
Ab, HuAChE, and Ab plus inhibitors at various concentrations in
0.215 M sodium phosphate buffer (pH 8.0) were prepared. The
final volume of each vial was 20 mL. Each assay was run in
duplicate. To quantify amyloid fibril formation, the thioflavin T
fluorescence method was then applied. After incubated at 37uC for
24 h, the solutions containing Ab,o rA b plus AChE, or Ab plus
AChE in the presence of inhibitors were added to 50 mM glycine–
NaOH buffer (pH 8.5) containing 1.5 mM thioflavin T in a final
volume of 2.0 mL. Fluorescence was monitored with excitation at
446 nm and emission at 490 nm soon after the solution was
mixed. The fluorescence intensities were compared and the
percent inhibition due to the presence of test compounds was
calculated. The percent inhibition of the HuAChE-induced
aggregation due to the presence of increasing test compound
concentration was calculated by the following expression:
1002(IFi/IFo6100) where IFi and IFo are the fluorescence
intensities obtained for Ab plus HuAChE in the presence or
absence of inhibitor, respectively. Inhibition curves were obtained
for each compound by plotting the percentage inhibition versus
the logarithm of inhibitor concentration in the assay sample. The
linear regression parameters were determined and the IC50
extrapolated, when possible (GraphPad Prism 3.0 GraphPad
Software Inc.).
Transmission electron microscopy (TEM) to assay the fAb
Assay of Ab1–40 fibril formation using TEM images as
previously described [25]. Briefly, TEM analysis was performed
to observe size and structural morphology changes of fAb1–40 in
the presence or absence of T6FA or FA at different concentrations.
A mixture of freshly prepared Ab1–40 solution (10 mLo f5 0mMi n
10 mM sodium phosphate at pH 7.4) was incubated for 72 h at
37uC. The TEM samples were prepared by placing 5 mL of the
pre-incubated solution on a carbon-coated grid. The samples were
stained with 1% uranyl acetate and were placed on a clean paper
Figure 1. Chemical structures of tacrine, ferulic acid, and the hybrid moleculeT6FA.
doi:10.1371/journal.pone.0031921.g001
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examined using a Phillips CM-30 electron microscope. Images
were recorded at 52,0006magnification in a Philips/FEI CM120
electron microscope with a Gatan GIF100 imaging filter, equipped
with a cooled slow scan CCD camera.
Cell Culture and Treatment
PC12 cells originally obtained from American Tissue Type Cell
Collection (ATCC) were grown in RPMI 1640 medium
supplemented with 10% horse serum, 5% fetal bovine serum,
and 1% antibiotics (penicillin/streptomycin) at 37uCi na
humidified 95% air/5% CO2 incubator. Cells were pretreated
with test compound and incubated for 30 min. After that, Ab1–40
solution (final concentration, 20 mM) was added to culture
medium and incubated for 24 h. Controls were only treated with
the vehicle or with the reverse peptide Ab40–1 (final concentration,
20 mM). The reverse sequence Ab40–1 was prepared in the same
way of that of Ab1–40.
Cell viability Assays
Assays for cell viability were performed after 24 h of Ab1–40 or
Ab40–1 treatment as previously described [26]. Photomicrographs
were taken with a camera attached to microscope (Olympus,
Japan) after 24 h of treatment to assess morphological alterations.
Cell viability was assessed by measuring formazan produced by the
reduction of MTT. PC12 cells in 48-well culture dishes were
treated with Ab and incubated for 24 h at 37uC. Briefly, after
treatment for 24 h, MTT solution (final concentration, 500 mg/
mL) was added and cells were incubated at 37uC for 1 h. After
this, the medium was removed and the cells were solubilized with
dimethylsulfoxide and transferred to a 96-well plate. The
formazan reduction product was measured by reading absorbance
at 560 nm in a plate reader (BioTek, China).
Reactive oxygen species (ROS) detection
Intracellular ROS formation was measured by fluorescence
using H2DCF-DA [27]. Briefly, PC12 cell cultures grown on 96-
well plates were incubated with 10 mMH 2DCF-DA (Molecular
Probes, agency in China) for 30 min at 37uC after 24 h of Ab1–40
treatment in the presence or absence of T6FA. The cells were then
rinsed with PBS solution. Intracellular esterases convert DCF
diacetate to anionic DCFH which is trapped in the cells. The
fluorescence of DCF, formed by the reaction of DCFH with ROS
was recorded (504 nm excitation, 529 nm emission) using a
PerkinElmer LS-5B spectrofluorometer.
Animals
The animal experiments were performed according to interna-
tionally followed ethical standards and approved by the research
ethics committee of Sun Yat-sen University (No 20081102). The
investigation conformed to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996). Specific
pathogen free SPF C57 BL/6J mice (male, weighing 18–20 g)
were supplied by the Experimental Animal Center of Sun Yat-sen
University (Guangzhou, China) and housed in separate cages in
standard conditions. Animals were housed in standard laboratory
conditions: air-conditioned room (20–25uC), 12 h light/dark
illumination cycle, free access to food and water.
Ab intracerebroventricular (icv) AD model and drugs
administration
Ab1–40 was prepared as stock solution at a concentration 0.6 mg/
mL in sterile 0.1 M phosphate-buffered saline (PBS) (pH 7.4), and
aliquots were stored at 220uC. Ab1–40 was aggregated by
incubation in sterile distilled water at 37uC for 4 d before use as
described previously [28]. Ab1–40 (400 pmol/mouse) or PBS was
administered by icv route using a microsyringe (10 mL, Hamilton)
that was inserted perpendicularly 3 mm deep through the skull.
Briefly, the C57 BL/6J mice were anesthetized with 10% chloral
hydrate (3.5 ml/kg body weight) dissolved in saline and then 3 mL
of Ab or sterile PBS was injected directly into the lateralventricle, at
the following coordinates from bregma taken from the atlas of
mouse [11]: anterioposterior (AP)=20.1 mm; mediolateral
(ML)=1 mm; and dorsoventral (DV)=23 mm. 1 mg T6FA was
dissolved in 0.15 mL PEG-400 and diluted by 0.35 mL saline for
T6FA (20 mg/kg), then diluted to one tenth by vehicle (PEG-
400:saline=3:7) for T6FA (2 mg/kg). After surgery, each mice was
randomly assigned to one of five groups (n=10) to receive an
intragastric administration of vehicle (Sham and Model), T6FA
(2 mg/kg and 20 mg/kg), Donepezil (5 mg/kg) for consecutively
21 d. The protocol was outlined in Figure 2.
Morris water maze (MWM) test
The testing procedure was carried out as described previously
[29]. The maze consists of 1 m diameter black circular pool with
side walls 30 cm high. The pool is filled with water at a temperature
of 21,25uC to a depth of 20 cm. The platform is hidden
approximately 1 cm below the surface of the water in the 3rd
quadrant. 16 d after Ab1–40 administration, five groups were
subjected to the MWM as described. Prior to first trial of each day,
mice were placed on platform for 30 s for spatial orientation. Then
mice were placed in a random start site, facing tank wall, initially
mice were trained for 4 d for hidden platform trial, at 4th day were
trained for probe trial after hidden platform trial. The escape
latency is recorded as a parameter for hidden platform trial, and the
time spent in goal area is recorded as a parameter for probe trial.
Measurement of choline acetyltransferase (ChAT) and
AChE activity
Following MWM test, animals of each group were decapitated
under anesthesia at d22 after Ab1–40 administration. The brains
Figure 2. Experimental schedules.
doi:10.1371/journal.pone.0031921.g002
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Samples were weighed and homogenized to 10% homogenate
(100 mg sample in 1 mL ice-cold saline) for AChE. Aliquote of the
homogenate were further diluted with saline to 5% for ChAT assay.
The supernatant was used to determine AChE and ChAT activity
respectively. Protein concentration was determined by the method
of BCA. The activities of ChAT and AChE were determined
spectrophotometrically using the assay kit from Nanjing Jiancheng
Bioengineering Institute (Nanjing, China). The absorbance was
read at 324 nm, and ChAT activity was expressed as unite per g
protein. For the assay of AChE activity, a reaction mixture that
contained sodium phosphate (1 mM, pH 8.0) 470 ml, 2% DTNB
167 ml and 33 ml of homogenate was incubated for 5 min at 37uC.
Then,acetylcholineiodide (2 mM)280 mlwasadded to the reaction
mixture. After incubation for 3 min at 37uC, the reaction was
terminated by adding 50 ml of neostigmine (4 mM). The absor-
bance was measured at 412 nm at room temperature. AChE
activities were expressed as mmol per mg of protein.
Measurement of superoxide dismutase (SOD) activity and
malondialdehyde (MDA) level
MDA level and SOD activity were detected using commercial
kits (Nanjing Jiancheng Biotech., China) in tissue homogenates
dilutedto 10% and prepared in accordancewith the manufacturer’s
instructions. The 10% homogenate made as described before was
also used here for MDA assay and diluted with saline for the
determination of SOD activity. Activity of SOD in hippocampus
was measured by the method reported using nicotinamide adenine
denucleotide reduced form as a substrate [30]. The SOD activity
was expressed as units/mg protein. One unit of the enzyme was the
amount required to inhibit the rate of chromogen formation by
50%. As a measure of lipid peroxidation, MDA levels in brain tissue
wereestimatedby measuring thiobarbituric acid reactive substances
following the standard protocol using MDA detection kit and were
expressed as nmol per mg of protein (nmol per mg protein).
Statistical Analysis
The means and standard errors of means (SEM) were calculated
for all experiments. The data were subjected to one-way analysis of
variance (ANOVA) followed by Duncan’s multiple-range test to
determine whether means were significantly different from the
control or model. In all cases, a P value of ,0.05 was accepted to
determine the significance.
Results
Effect of T6FA on AChE-induced and auto-aggregation of
Ab
Accumulating evidence demonstrates that AChE has secondary
non-cholinergic functions including the processing and deposition
of Ab [31]. AChE can accelerate Ab deposition through its
peripheral anionic site (PAS). Compounds binding to the PAS can
inhibit AChE-accelerated fibril aggregation. T6FA is a novel dual-
binding site AChE inhibitor which can modulate both the
cholinergic and amyloid targets [17,19], indicating that T6FA
may inhibit Ab aggregation and deposition. To assess T6FA’s
ability of inhibiting Ab aggregation induced by AChE, a thioflavin
T-based fluorometric assay was used [24]. As shown in Table 1,
T6FA significantly inhibited the AChE-induced Ab1–40 aggrega-
tion by 50.27% and 20.23% at 100 mM and 50 mM, respectively,
while the effects of FA and tacrine on Ab aggregation were lower
or not detected at such concentrations.
It was well documented that antioxidants, including FA, can
inhibit Ab auto-aggregation [13]. To further observe the effects of
T6FA on the auto-aggregation of Ab, the transmission electron
microscopy (TEM) was used. Ab became long and network fibrils
after incubating for 72 h (Figure 3). The fibrils Ab were
significantly decayed when FA or T6FA (10–25 mM) was present.
It is noteworthy that T6FA almost completely inhibited fibril
production at 25 mM. (Figure 3).
T6FA prevents the cell death and reduces intracellular
ROS induced by Ab1–40 in PC12 cells
Ab-induced apoptotic neuronal cell death is a critical event in
the pathology of AD. To investigate whether T6FA can attenuate
the cell death induced by Ab1–40, PC12 were pretreated with
T6FA (2–50 mM) for 30 min and then exposed to 20 mMA b1–40
for 24 h before cell viability was assayed. Phase contrast images
showed that the cells were fewer in number, less viable with
shrinked cell body, many fragments, and less adhered after the
Table 1. T6FA Inhibits AChE-induced Ab aggregation.
Compound % inhibition of Ab Aggregation
a
100 mM
b (%) 50 mM
c (%)
T6FA 50.27 20.23
1(tacrine) 8.31 NA
d
2(ferulic acid) 28.66 7.5
aCo-aggregation inhibition of Ab1–40 20 mM and AChE 0.02 U was detected by
thioflavin T assay.
bThe data (%) showed that the test compounds inhibited the coaggregation at
100 mM.
cThe data (%) showed that the test compounds inhibited the co-aggregation at
50 mM.
dNd represents for ‘‘not available’’.
doi:10.1371/journal.pone.0031921.t001
Figure 3. T6FA inhibits the Ab auto-aggregation. Electron
micrographs of Ab1–40 were taken with or without ferulic acid (FA)
and T6FA. The reaction mixture containing 25 mMA b1–40,5 0 m M
phosphate buffer, pH 7.5, 100 mM NaCl, and 5–25 mM FA or T6FA was
incubated at 37uC for 24 h. Scale bar=100 nm.
doi:10.1371/journal.pone.0031921.g003
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of Ab1–40 (Figure 4A). Cell viability assay inT6FA dramatically
prevented the cell death induced by Ab1–40 in PC12 cells even in
2 mM, while the reverse sequence of Ab40–1 had no effect on the
cell viability (Figure 4B). Although inducing some toxicity at
50 mM, T6FA still attenuated the Ab1–40-mediated cell death at
such concentration (Figure 4B).
Oxidative stress plays a pivotal role in the progression of AD
and Ab can induced neuronal cell death and intracellular ROS
accumulation [3]. In present study, Ab1–40 (20 mM) increased the
intracellular ROS accumulation by about 2.0-folds after 24 h in
the PC12 cells. Treatment of T6FA (10 mM) profoundly reduced
the Ab1–40-induced production of ROS to basal levels without
affecting basal levels of ROS (Figure 5).
Effect of T6FA on the cognitive impairment in Ab icv
mice
The effect of T6FA (2 mg/kg, 20 mg/kg, i.g.) on spatial
learning was evaluated by MWM test in an AD model in mice. As
shown in Figure 6 A, the mice in model group exhibited longer
escape latency than that in sham-operated group during the test
(P,0.01). The increased escape latencies could be significantly
attenuated by Donepezil (5 mg/kg) at d1, d2 and d4 (P,0.05).
T6FA (20 mg/kg) could markedly shorten the increased escape
latencies and such effects were mostly significant from d2
(P,0.01). T6FA (2 mg/kg) showed the same effect at the last
two days. In the probe trial, swimming times within the target
quadrant of mice in the model group were obviously less than
those in the sham-operated group (Figure 6 B). However, the
shortened swimming time within the platform quadrant induced
by Ab was increased by the treatment of T6FA (2 mg/kg and
20 mg/kg). No significant difference was found between donepezil
treatment and high dose T6FA treatment (Figure 6 B).
T6FA increases ChAT activity and decreases AChE activity
in Ab icv mice
ChAT activity and AChE activity were measured after the
learning and memory tests. As shown in Table 2, compared with
the sham-operated group, the ChAT activity was significantly
Figure 4. T6FA inhibits Ab-induced cell death in PC12 cells.
PC12 cells were pretreated with T6FA (2–50 mM) for 30 min, before
exposure to Ab1–40 (20 mM) or the reverse peptide Ab40–1 or vehicle for
additional 24 h. The cellular viability was evaluated by phase-contrast
microscopy observation (A) and MTT assay (B). (A) Representative
phase-contrast photographs of PC12 cells: a, control; b, Ab1–40; c, T6FA
and d, T6FA plus Ab1–40. Scale bar=50 mM. (B) The data were expressed
as percentage of the control (non-treated cells). The control treatment
is set to 100%. Bars are means 6 S.E. We used ** P,0.01 and * P,0.05
versus control, ##P,0.01 versus Ab1–40 treatment (n=6).
doi:10.1371/journal.pone.0031921.g004
Figure 5. T6FA inhibits Ab1–40-induced intracellular ROS accumulation in PC12 cells. Treatment of cells and measurement of oxidative
stress levels using the DCF-DA assay were as described in Materials and Methods section. The data were expressed as the mean 6 S.E.M. as a
percentage of control values. Statistical comparison was analyzed by ANOVA (n=5). **P,0.01, Ab1–40 versus Control.
doi:10.1371/journal.pone.0031921.g005
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donepezil treatments dramatically reversed this change. In
contrast, the AChE activity was significantly elevated in hippo-
campus in the model mice, which was reversed to normal levels of
mice in sham group.
T6FA decreases the oxidative stress in Ab icv mice
To evaluate the effects of T6FA on the oxidative stress in Ab icv
mice, SOD activity and MDA level, two factors indicating the
oxidative stress, were also assayed after the MWM test. The SOD
activity in model group was significantly lower than that in sham-
operated group (P,0.05), while the SOD activity was significantly
increased (P,0.05) by T6FA (2 mg/kg) (from 127 to 161 U/mg
protein). Interestingly, the effects of T6FA (20 mg/kg) was milder
(P,0.01, Table 3). In contrast, the MDA level was significantly
higher in hippocampus in model mice than that in sham-operated
group (P,0.05). All the treatments markedly reversed the
increased MDA level (P,0.01, Table 3).
Discussion
In the present study, we evaluated the multiple-potent effects of
T6FA against AD both in vitro and in vivo. Our in vitro results
demonstrated that T6FA significantly inhibited Ab aggregation
induced by AChE, and blocked the cell death and the intracellular
ROS accumulation induced by Ab in PC12 cells. Moreover, we
also observed that T6FA significantly improved the cognitive
Figure 6. T6FA improves the cognitive impairment in Ab1–40-injected mice. Ab1–40 (400 pmol/mouse) or PBS was administered by icv route
using a microsyringe. After surgery, each mouse received an intragastric administration of vehicle (Sham and Model), T6FA (2 mg/kg and 20 mg/kg),
Donepezil (5 mg/kg) for consecutive 21 d. The MWM test was used to observe the spatial learning and memory performance of mice at d16 after
surgery. Escape latencies in hidden-platform (A) and spatial preference pattern in a probe test (B). T6FA treatment could significantly shorten the
escape latency and increase the swimming time in object quadrant compared with model mice. Data were presented as mean 6 S.E.M. (n=10).
*P,0.05, **P,0.01 versus sham-operated group;
# P,0.05,
##P,0.01 versus model group.
doi:10.1371/journal.pone.0031921.g006
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AChE activity and MDA level in Ab i.c.v. AD model.
Diverse lines of evidence suggest that Ab plays a causal role in
the pathogenesis of AD, the most frequent neurodegenerative
disorder and the most common cause of dementia in the elderly
[32]. Prefibrillar oligomers of the Ab are recognized as potential
mediators of AD pathophysiology. Increasing evidence showed
that AChE is one of the several proteins associated with Ab
aggregation and amyloid plaque deposits [31,33,34]. Recently,
novel dual inhibitors of AChE that target both the catalytic site
as well as the peripheral anionic site (PAS) were found to prevent
the aggregation of Ab into Alzheimer’s fibrils [35,36]. Our
previous research found that novel compound T6FA could
inhibit AChE through interacting with the catalytic site and PAS
simultaneously [17,19], suggesting that T6FA might inhibit
AChE-induced Ab aggregation. Here we demonstrated that
T6FA dramatically inhibit AChE-induced Ab aggregation by
50.27% and 20.23% at 100 mMa n d5 0 mM, respectively
(Table 1). In addition, phenolic compounds, including FA, can
inhibit the Ab auto-aggregation [13]. So, we further investigated
the effects of T6FA on the auto-aggregation of Ab.W ef o u n d
that T6FA (10–25 mM) remarkably inhibited the auto-aggrega-
tion of Ab (Figure 3). Given the toxicity of Ab is mainly
mediated by the prefibrillar oligomers of Ab and Ab-induced
ROS [5–8], we hypothesized that T6FA could block the Ab-
induced cell death through its anti-oxidant activity and anti-
aggregation.
In the present study, we have shown that in PC12 cells, T6FA
(2–50 mM) prevents the neurotoxicity induced by Ab1–40,a
proteolytic derivative of the large transmembrane amyloid
precursor protein, which plays a crucial role in AD (Figure 4A).
Free-radical oxidative stress, particularly of neuronal lipids,
proteins and DNA, is extensive in those AD brain areas in which
Ab is abundant and even those mild cognitive impairment brains
[5–8,37]. Our previous research demonstrated that T6FA has
antioxidant activity determined by scavenging stable DPPH
radicals [17,19]. DPPH radicals are widely used for the
preliminary screening of compounds capable of scavenging
activated oxygen species since they are much more stable and
easier to handle than oxygen free radicals [38,39]. Ab was
reported to significantly increase intracellular ROS [5–8,37]. In
the present study, Ab1–40 significantly induced ROS accumulation
in PC12 cells and the effects can be reversed completely by the
pre-treatment of T6FA at 10 mM (Figure 4B).
Clearly, T6FA has protective effects against cholinergic
deficiency, oxidative stress and Ab toxicity in vitro. However, the
protective effects of T6FA in vivo were still unknown. Our previous
research found that T6FA can improve the scopolamine-induced
cognitive dysfunction in mice [17]. These results suggested that
T6FA can penetrate the blood-brain barrier into brain. So we
further investigated the effects of T6FA in AD mice induced by
Ab1–40, which had been evaluated as a validated animal model for
anti-AD drugs development [40]. Following the central adminis-
tration of the synthetic peptides Ab1–40 analogous to peptides
found in neuritic plaques of AD patients, cognitive deficits emerge
in mice [26]. In our study, T6FA significantly reduced the escape
latency during the hidden platform sessions and also increased the
time in the target quadrant as compared with model group
(P,0.05) (Figure 6), indicating that T6FA could ameliorate the
impairment of learning and memory following Ab1–40 adminis-
tration.
We also measured the inhibitory effects of T6FA on cholinergic
systems and anti-oxidative activity in AD mice. Our results showed
that T6FA could significantly increased ChAT and SOD activity,
decreased AChE activity and MDA level, indicating it also has
ability of antioxidation and inhibiting cholinergic deficiency in vivo
(Table 2 and Table 3). Meanwhile, we found that no significance
was observed in the high and low doses of T6FA (20 mg/kg and
2 mg/kg) while the some better effects on the activities of ChAT
and SOD were observed in 2 mg/kg group, which maybe due to
the fact that T6FA might down-regulate the SOD expression at
the high dose. But further studies should be carried out to uncover
it, such as using RT-PCR or western blotting to detect the levels of
mRNA/protein of SOD. Further studies should be carried out to
answer the question.
In addition, increasing evidences indicated that AChE inhibi-
tors, such as tacrine [41] and rivastigmine [42], lower the amyloid
protein in vitro independent of their AChE inhibitory. It should be
very interesting whether T6FA can also modulate the level of
amyloid protein or not. Future studies are needed to be done to
discover the question in vitro and in vivo.
Taken together, the present study demonstrated that, T6FA, a
new tacrine-ferulic acid heterodimer, potently inhibit auto- and
AChE-induced aggregation. Further, the findings that T6FA
blocks or prevents Ab1–40 induced cell death and ROS in vitro and
chronically oral administration of T6FA protected mice against
Ab1–40-induced cognitive impairment in vivo strongly suggest that
T6FA is a novel ‘‘one-compound-multi-targets’’ agent and might
be useful as preventive and therapeutic medicines for AD.
Additional in vitro and in vivo studies in other models to uncover
the anti-AD effects of the novel compound are currently underway
in our laboratory.
Table 2. Effects of T6FA on ChAT and AChE activity of in
hippocampus of Ab1–40 icv C57 BL/6J mice.
Groups ChAT (U/g protein) AChE (U/mg protein)
Sham 94.84611.22 0.1360.005
Model 30.0065.95* 0.1860.007**
T6FA (2 mg/kg) 73.6366.55
## 0.1260.010
##
T6FA (20 mg/kg) 61.4167.68
# 0.1360.012
##
Donepezil (5 mg/kg) 59.3968.74
# 0.1360.005
##
Data were presented as mean 6 S.E.M. n=10;
*P,0.05,
**P,0.01 compared with sham-operated group;
#P,0.05,
## P,0.01 compared with model group.
doi:10.1371/journal.pone.0031921.t002
Table 3. Effects of T6FA on SOD activity and MDA level
in hippocampus of C57 BL/6J mice by the i.c.v. injection of
Ab1–40.
Groups SOD (U/mg protein) MDA (nmol/mg protein)
Sham 154.9368.62 0.6660.09
Model 127.1067.49* 1.0560.10*
T6FA (2 mg/kg) 161.1067.21
# 0.7260.14
#
T6FA (20 mg/kg) 139.1867.43 0.7060.08
#
Donepezil (5 mg/kg) 168.0368.26
## 0.5860.07
##
Data were presented as mean 6 S.E.M. n=10;
*P,0.05,
#P,0.05,
## P,0.01 compared with model group.
doi:10.1371/journal.pone.0031921.t003
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